Arseniy Tsapenko
Pulmonary Disease · Knoxville, TNNPI 1962604140
Payments from drug & device makers
Across 217 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$738
- Actelion Pharmaceuticals US, Inc.$445
- Insmed, Inc.$306
- AstraZeneca$258
- Merck$256
- Boehringer Ingelheim$245
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,795100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 51 | $738 |
| Actelion Pharmaceuticals US, Inc. | 28 | $445 |
| Insmed, Inc. | 15 | $306 |
| AstraZeneca(2 entities) | 17 | $258 |
| Merck | 12 | $256 |
| Boehringer Ingelheim | 14 | $245 |
| AbbVie | 13 | $216 |
| Grifols USA, LLC | 12 | $210 |
| Mylan Specialty L.p. | 8 | $123 |
| Regeneron Healthcare Solutions, Inc. | 6 | $111 |
| Breas Medical, Inc. | 1 | $93 |
| United Therapeutics Corporation | 4 | $92 |
| Genentech USA, Inc. | 5 | $82 |
| Sanofi | 3 | $72 |
| Mallinckrodt Hospital Products Inc. | 3 | $60 |
| Olympus America Inc. | 1 | $59 |
| Viatris Specialty LLC | 3 | $55 |
| Novartis | 3 | $49 |
| Johnson & Johnson | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Pfizer | 2 | $32 |
| Philips North America LLC | 1 | $31 |
| Pulmonx Corporation | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Electromed, Inc. | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Baxter Healthcare | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Gilead | 1 | $15 |
| Ambu Inc. | 1 | $14 |
| Circassia Inc. | 1 | $13 |
How this compares
$3,811 in reported general payments places this provider in the 45th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Knoxville
- John SwisherKnoxville$2.3M
- Eric WeaverKnoxville$492K
- Rajiv DhandKnoxville$426K
- John CallisonKnoxville$324K
- John PrinceKnoxville$117K
- Isaac BineyKnoxville$73K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Bashar BargotyKnoxville$28K
- Zulma SwankKnoxville$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.